G蛋白偶聯受體市場－全球產業規模、佔有率、趨勢、機會、預測：按產品、檢測類型、應用、地區和競爭對手分類，2021-2031年

全球 G 蛋白偶聯受體 (GPCR) 市場預計將從 2025 年的 40.6 億美元成長到 2031 年的 55.3 億美元，複合年成長率為 5.29%。

該市場涵蓋專門用於研究和靶向G蛋白偶聯受體（GPCR）的技術、檢測方法和治療藥物的商業化。 GPCR是真核生物中最大的細胞表面受體家族。這些關鍵受體透過感知外部訊號並觸發細胞內反應，在調節重要的生理過程中發揮基礎性作用，從而構成了現代藥理學的核心。市場擴張的主要驅動力是全球慢性疾病（例如心血管疾病和代謝性疾病）發病率的不斷上升，這推動了對創新標靶治療方法的需求。此外，結構生物學，特別是冷凍電鏡技術的突破性進展，使得以前難以發現的受體配體的精確開發成為可能，極大地促進了行業成長。儘管前景光明，但該市場仍面臨許多挑戰，包括功能性受體分離過程中固有的結構不穩定性及複雜性。這些挑戰使藥物發現過程複雜化，推高了研發成本，並導致臨床試驗的高失敗率。然而，根據美國製藥商協會 (PhRMA) 的一份報告，截至 2024 年，有近 800 種治療慢性疾病的藥物正在研發中，這凸顯了儘管存在技術挑戰，但對以 GPCR 為中心的篩檢和檢驗技術的持續需求。

市場促進因素

基於結構的藥物發現和冷凍電鏡技術的進步正在從根本上改變全球G蛋白偶聯受體（GPCR）市場，使精準標靶化先前被認為無法治療的受體成為可能。冷凍電鏡技術使研究人員能夠在原子層面上觀察複雜的受體結構，從而能夠設計口服小分子化合物，用於治療先前只能透過注射胜肽類療法才能靶向的目標。這項技術革新正在產生重大影響，尤其是在代謝領域，新的平台正在有效解決與B類GPCR相關的穩定性問題。例如，2024年6月，Structure Therapeutics公司報告稱，其在研口服小分子GLP-1受體促效劑GSBR-1290在一項IIa期肥胖治療試驗中，實現了安慰劑校正後的平均體重減輕6.2%，展現了此類創新治療方法的商業性潛力。另一個關鍵促進因素是研發投入的大幅成長。這代表著投資的顯著成長，其驅動力來自於闡明罕見疾病和複雜受體家族的巨大潛在利益。生物製藥公司正在籌集大量資金，以實現專有平台產業化，而這些平台對於分離功能性受體至關重要，這是現代藥物篩檢的先決條件。這種強勁的財務信心在近期的公開市場活動中顯而易見。例如，Septerna公司於2024年10月進行的首次股票公開發行（IPO）籌集了約3.312億美元，用於推進其「天然複雜平台」和產品管線。此外，諸如羅氏公司於2024年8月以27億美元收購Carmot Therapeutics公司，以獲得臨床階段代謝疾病相關資產等高價值併購，進一步凸顯了該領域的戰略重要性和持續投資。

市場挑戰

分離功能性G蛋白偶聯受體（GPCR）的結構不穩定性及其固有的複雜性構成了阻礙市場成長的重大技術障礙。這些跨膜蛋白一旦脫離細胞膜，往往會失去其天然構象，使得研究人員難以確保其具有足夠的穩定性，從而難以進行有效的檢測方法開發和配體篩檢。這種不穩定性削弱了藥物舉措的可信度，常常導致篩選出的候選化合物在生理條件下可能無效。因此，製藥業的藥物研發流程效率低且進展緩慢，因為大量資源被浪費在無法透過傳統分離技術處理的標靶上。這種技術上的不確定性直接增加了研發成本，並導致後期研究階段的高失敗率。這些低效率帶來的經濟影響巨大，迫使製藥業為每種成功的療法承擔巨額沉沒成本。為了說明應對這些挑戰所需的資金規模，歐洲製藥工業協會 (EFPIA) 估計，到 2024 年，歐洲製藥業將在研發方面投資約 550 億歐元。這筆投資中的很大一部分都消耗在了針對複雜膜蛋白時固有的高失敗率上，這反過來又限制了該行業的整體盈利和成長率。

市場趨勢

人工智慧 (AI) 和機器學習 (ML) 的快速應用正顯著推動全球 G 蛋白偶聯受體 (GPCR) 市場的發展，有效克服了結構建模和配體發現的傳統障礙。與傳統的篩檢方法不同，這些計算技術使研究人員能夠以前所未有的速度和精確度預測複雜受體的3D結構，並設計新型候選藥物。對於結構數據通常有限的罕見 GPCR 而言，這種能力尤其重要，它使得研究人員能夠有效地識別有前景的治療資產，而無需完全依賴繁瑣的實驗結晶。例如，2025 年 3 月，《製藥技術》雜誌報道稱，Google支援的 Isomorphic Labs 在早期外部資金籌措輪中獲得了 6 億美元，旨在加速其人工智慧驅動的藥物發現引擎。這凸顯了業界對計算方法在攻克疑難雜點方面的巨大信心。同時，針對 GPCR 的單株抗體和奈米抗體的研發也顯著增加，這標誌著治療策略正從傳統上占主導地位的小分子療法轉向其他療法。這種轉變的驅動力在於生物製藥具有更高的特異性和可調控的藥物動力學特性，這顯著降低了化學配體通常伴隨的脫靶毒性。透過利用專門的藥物發現平台，研發人員可以設計出能夠穩定特定受體構象的高精度抗體，從而為以往只能使用選擇性較低的藥物治療的慢性疾病開闢新的治療途徑。大量資金的流入進一步推動了向大分子療法的策略性轉變。例如，Tectonic Therapeutic公司於2025年2月宣布獲得約1.85億美元的私募股權資金籌措，用於加速其專有GEODe平台和新型GPCR標靶治療蛋白管線的開發。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球G蛋白偶聯受體市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依產品分類（細胞株、​​檢測試劑盒、細胞培養試劑、配體）
  • 檢測類型（cAMP 功能檢測、鈣功能檢測、BETA-澱粉樣蛋白功能檢測、放射性配體結合和 GTPY 功能檢測、內部攝取檢測、轉運檢測、其他）
  • 按應用領域（癌症研究、中樞神經系統研究、代謝研究、心血管研究、呼吸系統研究、發炎研究等）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美G蛋白偶聯受體市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲G蛋白偶聯受體市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區G蛋白偶聯受體市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲G蛋白偶聯受體市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲G蛋白偶聯受體市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球G蛋白偶聯受體市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Thermo Fisher Scientific Inc.
• PerkinElmer Inc.
• Promega Corporation
• Merck KGaA
• Abcam plc
• Becton, Dickinson and Company
• Danaher Corporation
• QIAGEN NV
• Bio-Techne Corporation
• WuXi AppTec

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global G-Protein Coupled Receptors (GPCR) Market is projected to expand from USD 4.06 billion in 2025 to USD 5.53 billion by 2031, demonstrating a compound annual growth rate (CAGR) of 5.29%. This market encompasses the commercialization of technologies, assays, and therapeutic agents specifically designed to investigate and target G-Protein Coupled Receptors, which represent the largest family of cell surface receptors in eukaryotic organisms. These crucial receptors play a fundamental role in regulating vital physiological processes by detecting external signals and initiating internal cellular responses, thereby forming a core pillar of contemporary pharmacology.nThe market's expansion is predominantly fueled by the increasing global incidence of chronic diseases, such as cardiovascular and metabolic disorders, which drives the demand for innovative, targeted treatments. Furthermore, breakthroughs in structural biology, particularly cryo-electron microscopy, are facilitating the precise development of ligands for receptors previously deemed difficult to drug, contributing significantly to industry growth. Despite these promising prospects, the market contends with substantial obstacles, including the inherent structural instability and intricate nature of isolating functional receptors, which complicates drug discovery and inflates development costs, alongside high attrition rates in clinical trials. Nevertheless, the substantial pipeline of nearly 800 medicines under development for chronic conditions in 2024, as reported by the Pharmaceutical Research and Manufacturers of America, highlights the enduring need for GPCR-focused screening and validation technologies, despite technical difficulties.

Market Driver

Technological advancements in structure-based drug design and cryo-electron microscopy are fundamentally transforming the Global G-Protein Coupled Receptors Market by enabling the precise targeting of receptors that were previously considered undruggable. Improvements in cryo-EM now provide researchers with atomic-resolution views of intricate receptor structures, making it possible to engineer oral small molecules for targets that were traditionally addressed only by injectable peptide therapies. This technical evolution is particularly impactful within the metabolic sector, where novel platforms are successfully addressing the stability issues associated with Class B GPCRs; for instance, Structure Therapeutics reported in June 2024 that its investigational oral small molecule GLP-1 receptor agonist, GSBR-1290, achieved a 6.2% placebo-adjusted mean weight loss in a Phase 2a obesity study, validating the commercial potential of these innovative modalities.nA second crucial driver is the significant increase in R&D investments dedicated to developing novel GPCR therapeutics, fueled by the substantial return potential from unlocking orphan and complex receptor families. Biopharmaceutical firms are attracting considerable capital to industrialize proprietary platforms essential for isolating functional receptors, a prerequisite for modern drug screening. This robust financial confidence is evident in recent public market activities, such as Septerna's October 2024 initial public offering, which raised approximately $331.2 million to advance its Native Complex Platform and pipeline. Furthermore, high-value consolidation deals, like Roche's reported acquisition of Carmot Therapeutics for $2.7 billion in August 2024 to secure clinical-stage metabolic assets, further underscore the strategic importance and sustained investment in this sector.

Market Challenge

The structural instability and inherent complexity involved in isolating functional G-protein coupled receptors present a significant technical barrier that impedes market growth. Because these transmembrane proteins frequently lose their native conformation once removed from the cellular membrane, researchers encounter profound difficulties in stabilizing them sufficiently for effective assay development and ligand screening. This instability undermines the reliability of drug discovery initiatives, often resulting in the selection of candidates that may prove ineffective in a physiological context. Consequently, the industrial drug discovery pipeline becomes slower and less efficient, as considerable resources are expended on targets that prove unmanageable using conventional isolation techniques.nThis technical unpredictability directly inflates development costs and contributes to elevated attrition rates during the later phases of research. The financial repercussions of such inefficiencies are substantial, forcing the industry to absorb significant sunk costs for each successful therapeutic. To illustrate the scale of financial commitment required to navigate these challenges, the European pharmaceutical industry invested an estimated 55 billion euros in research and development in 2024, according to the European Federation of Pharmaceutical Industries and Associations. A considerable portion of this investment is consumed by the high failure rates inherent in targeting complex membrane proteins, thereby constraining the overall profitability and expansion velocity of the sector.

Market Trends

The rapid integration of artificial intelligence (AI) and machine learning (ML) is significantly advancing the Global G-Protein Coupled Receptors Market by effectively overcoming traditional obstacles in structural modeling and ligand discovery. Unlike conventional screening methodologies, these computational technologies empower researchers to predict the three-dimensional structures of complex receptors and design novel therapeutic candidates with unprecedented speed and precision. This capability is particularly transformative for orphan GPCRs, where structural data is often limited, enabling the efficient identification of viable therapeutic assets without relying solely on laborious experimental crystallization. For instance, Pharmaceutical Technology reported in March 2025 that Isomorphic Labs, with Google's backing, secured $600 million in its initial external funding round specifically to accelerate its AI-driven drug design engine, underscoring the immense industrial confidence in computational approaches to tackle challenging targets.nConcurrently, the market is observing a notable rise in the development of monoclonal antibodies and nanobodies aimed at GPCRs, marking a departure from the historical prevalence of small molecule therapies. This shift is driven by the superior specificity and adjustable pharmacokinetics offered by biologics, which significantly mitigate the off-target toxicity often associated with chemical ligands. By utilizing specialized discovery platforms, developers can now engineer highly precise antibodies capable of stabilizing specific receptor conformations, thereby providing new treatment avenues for chronic conditions previously managed with less selective agents. This strategic move towards large-molecule therapeutics is further supported by substantial capital inflows, as evidenced by Tectonic Therapeutic, Inc. announcing in February 2025 an approximately $185 million private investment in public equity financing to advance its proprietary GEODe platform and pipeline of novel GPCR-targeted therapeutic proteins.

Key Market Players

• Thermo Fisher Scientific Inc.
• PerkinElmer Inc.
• Promega Corporation
• Merck KGaA
• Abcam plc
• Becton, Dickinson and Company
• Danaher Corporation
• QIAGEN N.V.
• Bio-Techne Corporation
• WuXi AppTec

Report Scope

In this report, the Global G-Protein Coupled Receptors Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

G-Protein Coupled Receptors Market, By Product

• Cell Lines
• Detection Kits
• Cell Culture Reagents
• Ligands

G-Protein Coupled Receptors Market, By Assay Type

• cAMP Functional Assays
• Calcium Functional Assays
• B-Arrestin Functional Assays
• Radioligand Binding & GTPYS Functional Assays
• Internalization Assays
• Trafficking Assays
• Others

G-Protein Coupled Receptors Market, By Application

• Cancer Research
• CNS Research
• Metabolic Research
• Cardiovascular Research
• Respiratory Research
• Inflammation Research
• Others

G-Protein Coupled Receptors Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global G-Protein Coupled Receptors Market.

Available Customizations:

Global G-Protein Coupled Receptors Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global G-Protein Coupled Receptors Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Cell Lines, Detection Kits, Cell Culture Reagents, Ligands)
  • 5.2.2. By Assay Type (cAMP Functional Assays, Calcium Functional Assays, B-Arrestin Functional Assays, Radioligand Binding & GTPYS Functional Assays, Internalization Assays, Trafficking Assays, Others)
  • 5.2.3. By Application (Cancer Research, CNS Research, Metabolic Research, Cardiovascular Research, Respiratory Research, Inflammation Research, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America G-Protein Coupled Receptors Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Assay Type
  • 6.2.3. By Application
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States G-Protein Coupled Receptors Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Assay Type
      • 6.3.1.2.3. By Application
  • 6.3.2. Canada G-Protein Coupled Receptors Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Assay Type
      • 6.3.2.2.3. By Application
  • 6.3.3. Mexico G-Protein Coupled Receptors Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Assay Type
      • 6.3.3.2.3. By Application

7. Europe G-Protein Coupled Receptors Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Assay Type
  • 7.2.3. By Application
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany G-Protein Coupled Receptors Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Assay Type
      • 7.3.1.2.3. By Application
  • 7.3.2. France G-Protein Coupled Receptors Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Assay Type
      • 7.3.2.2.3. By Application
  • 7.3.3. United Kingdom G-Protein Coupled Receptors Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Assay Type
      • 7.3.3.2.3. By Application
  • 7.3.4. Italy G-Protein Coupled Receptors Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Assay Type
      • 7.3.4.2.3. By Application
  • 7.3.5. Spain G-Protein Coupled Receptors Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Assay Type
      • 7.3.5.2.3. By Application

8. Asia Pacific G-Protein Coupled Receptors Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Assay Type
  • 8.2.3. By Application
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China G-Protein Coupled Receptors Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Assay Type
      • 8.3.1.2.3. By Application
  • 8.3.2. India G-Protein Coupled Receptors Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Assay Type
      • 8.3.2.2.3. By Application
  • 8.3.3. Japan G-Protein Coupled Receptors Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Assay Type
      • 8.3.3.2.3. By Application
  • 8.3.4. South Korea G-Protein Coupled Receptors Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Assay Type
      • 8.3.4.2.3. By Application
  • 8.3.5. Australia G-Protein Coupled Receptors Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Assay Type
      • 8.3.5.2.3. By Application

9. Middle East & Africa G-Protein Coupled Receptors Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Assay Type
  • 9.2.3. By Application
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia G-Protein Coupled Receptors Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Assay Type
      • 9.3.1.2.3. By Application
  • 9.3.2. UAE G-Protein Coupled Receptors Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Assay Type
      • 9.3.2.2.3. By Application
  • 9.3.3. South Africa G-Protein Coupled Receptors Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Assay Type
      • 9.3.3.2.3. By Application

10. South America G-Protein Coupled Receptors Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Assay Type
  • 10.2.3. By Application
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil G-Protein Coupled Receptors Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Assay Type
      • 10.3.1.2.3. By Application
  • 10.3.2. Colombia G-Protein Coupled Receptors Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Assay Type
      • 10.3.2.2.3. By Application
  • 10.3.3. Argentina G-Protein Coupled Receptors Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Assay Type
      • 10.3.3.2.3. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global G-Protein Coupled Receptors Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. PerkinElmer Inc.
• 15.3. Promega Corporation
• 15.4. Merck KGaA
• 15.5. Abcam plc
• 15.6. Becton, Dickinson and Company
• 15.7. Danaher Corporation
• 15.8. QIAGEN N.V.
• 15.9. Bio-Techne Corporation
• 15.10. WuXi AppTec

16. Strategic Recommendations

17. About Us & Disclaimer